Table 6 Overall survival of PD-L1, PD-1, CD8, CD4 and CD3 is shown for biopsies taken before chemotherapy (BCT) and biopsies taken after the last line of chemotherapy (ACT).

From: Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

BCT biopsies			ACT biopsies
	Median OS (months)	p value		Median OS (months)	p value
Tumour PD-L1 expression		0.67	Tumour PD-L1 expression		0.11
<1% (n = 52)	6.0		<1% (n = 47)	6.0
1–49% (n = 7)	1.0		1–49% (n = 9)	6.0
≥50% (n = 8)	3.0		≥50% (n = 13)	18.0
Stromal infiltration of PD-L1⁺ IC		0.81	Stromal infiltration of PD-L1⁺ IC		0.10
Low infiltration (n = 39)	6.0		Low infiltration (n = 45)	6.0
Intermediate infiltration (n = 15)	6.0		Intermediate infiltration (n = 14)	18.0
High infiltration (n = 11)	5.0		High infiltration (n = 8)	12.0
Stromal infiltration of PD-1⁺ IC		0.38	Stromal infiltration of PD-1⁺ IC		0.005
Low infiltration (n = 40)	5.0		Low infiltration (n = 41)	5.0
Intermediate infiltration (n = 17)	4.0		Intermediate infiltration (n = 17)	11.0
High infiltration (n = 9)	11.0		High infiltration (n = 12)	NR
Tumour infiltration of CD8⁺ IC		0.39	Tumour infiltration of CD8⁺ IC		<0.0001
Low infiltration (n = 37)	6.0		Low infiltration (n = 39)	4.0
Intermediate infiltration (n = 11)	5.0		Intermediate infiltration (n = 16)	8.0
High infiltration (n = 18)	5.0		High infiltration (n = 16)	NR
Stromal infiltration of CD8⁺ IC		0.26	Stromal infiltration of CD8⁺ IC		0.001
Low infiltration (n = 11)	6.0		Low infiltration (n = 18)	3.0
Intermediate infiltration (n = 28)	5.0		Intermediate infiltration (n = 17)	5.0
High infiltration (n = 27)	6.0		High infiltration (n = 35)	14.0
Stromal infiltration of CD3⁺ IC		0.22	Stromal infiltration of CD3⁺ IC		0.003
Low infiltration (n = 23)	5.0		Low infiltration (n = 26)	3.0
Intermediate infiltration (n = 26)	6.0		Intermediate infiltration (n = 23)	9.0
High infiltration (n = 17)	5.0		High infiltration (n = 20)	23.0
Stromal infiltration of CD4⁺ IC		0.2	Stromal infiltration of CD4⁺ IC		0.001
Low infiltration (n = 16)	6.0		Low infiltration (n = 15)	5.0
Intermediate infiltration (n = 19)	4.0		Intermediate infiltration (n = 17)	2.0
High infiltration (n = 31)	6.0		High infiltration (n = 37)	14.0
Combined tumour and stromal infiltration of CD8⁺ IC		0.12	Combined tumour and stromal infiltration of CD8⁺ IC		<0.0001
Low infiltration of tumour and stromal CD8⁺ IC (n = 28)	6.0		Low infiltration of tumour and stromal CD8⁺ IC (n = 31)	5.0
High infiltration of tumour or stromal CD8⁺ IC (n = 20)	4.0		High infiltration of tumour or stromal CD8⁺ IC (n = 11)	3.0
High infiltration of tumour and stromal CD8⁺ IC (n = 18)	6.0		High infiltration of tumour and stromal CD8⁺ IC (n = 28)	23.0
Combined stromal infiltration of PD-1⁺ and CD8⁺ IC		0.72	Combined stromal infiltration of PD-1⁺ and CD8⁺ IC		<0.0001
Low infiltration of stromal PD-1⁺ and CD8⁺ IC (n = 31)	5.0		Low infiltration of stromal PD-1⁺ and CD8⁺ IC (n = 30)	5.0
High infiltration of stromal PD-1⁺ or CD8⁺ IC (n = 17)	4.0		High infiltration of stromal PD-1⁺ or CD8⁺ IC (n = 15)	5.0
High infiltration of stromal PD-1⁺ and CD8⁺ IC (n = 18)	6.0		High infiltration of stromal PD-1⁺ and CD8⁺ IC (n = 24)	23.0
Combined stromal infiltration of PD-L1⁺ and CD8⁺ IC		0.83	Combined stromal infiltration of PD-1⁺ and CD8⁺ IC		0.002
Low infiltration of stromal PD-L1⁺ and CD8⁺ IC (n = 31)	6.0		Low infiltration of stromal PD-L1⁺ and CD8⁺ IC (n = 30)	3.0
High infiltration of stromal PD-L1⁺ or CD8⁺ IC (n = 15)	5.0		High infiltration of stromal PD-L1⁺ or CD8⁺ IC (n = 20)	8.0
High infiltration of stromal PD-L1⁺ and CD8⁺ IC (n = 19)	6.0		High infiltration of stromal PD-L1⁺ and CD8⁺ IC (n = 17)	23.0

Statistically significant p < 0.05 values are in bold

Back to article page

Table 6 Overall survival of PD-L1, PD-1, CD8, CD4 and CD3 is shown for biopsies taken before chemotherapy (BCT) and biopsies taken after the last line of chemotherapy (ACT).

Search

Quick links